Fruquintinib MoA and Toxicity Profile Overview
Key safety considerations for the use of fruquintinib are explored.
Source: onclive.com
📰 Toxicity Profile News
Toxicity Profile News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Toxicity Profile. Real-time updates on events, politics, business and more.
Key Considerations for Treating Patients Diagnosed With CLL and SLL
Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL.
Source: ajmc.com
Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431
Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
Benjamin Levy Randomized Phase First Line Selpercatinib Partnership With Non Small Cell Lung Cancer Lung Cancer
Source: onclive.com
Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR+/HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial
Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.
Aditya Bardia Datopotamab Deruxtecan Primary Results Randomized Phase Previously Treated Inoperable Metastatic Hormone Receptor Positive
Source: onclive.com
The Evolving Treatment Landscape of Small Cell Lung Cancer
Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.
Christian Groh Laurent Greiller Evolving Paradigms Evolving Treatment Landscape Small Cell Lung Small Cell Lung Cancer
Source: onclive.com
Clinical Data With Lurbinectedin in Small Cell Lung Cancer
Key opinion leaders share a focused discussion on lurbinectedin and its evolving role in small cell lung cancer following frontline therapy.
Evolving Paradigms Data With Lurbinectedin Small Cell Lung Small Cell Lung Cancer Limited Stage Sclc Extensive Stage Sclc
Source: onclive.com
Dr Mina on the Evolution of T-DM1 and T-DXd in HER2+ Breast Cancer
Lida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.
United States Lidaa Mina Division Of Hematology Mayo Clinic Comprehensive Cancer Center Women Cancer Program Cancer Program
Source: onclive.com
HER2+ Metastatic Breast Cancer: An Evolving Treatment Armamentarium
Comprehensive insight on the treatment armamentarium currently available to patients with HER2+ metastatic breast cancer and CNS disease.
Improving Outcomes Breast Cancer Translating Evidence Clinical Practice Metastatic Breast Cancer Her2 Breast Cancer
Source: onclive.com
Dr Desai on Toxicities Associated with T-DXd in HER2+ Breast Cancer
Neelam Desai, MD, discusses the toxicity profile of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
Neelam Desai Levine Cancer Institute Atrium Health Toxicity Profile Her2 Positive Breast Cancer Fam Trastuzumab Deruxtecan Nxki
Source: onclive.com
Head-to-Head Studies on BTK Inhibitors in CLL
CLL expert Lori A. Leslie, MD, gives a comprehensive overview of the ALPINE and ELEVATE-RR head-to-head studies of BTK inhibitors in CLL.
Source: curetoday.com